Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Active, not recruiting · NCT02406222 · Registry updated 2024-12-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2024-12-05 | NCT02406222 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celgene | 53 |
| Myeloma UK | 1 |
| University of Leeds | 70 |
21 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.